Kaj je EFFICACY HAS BEEN DEMONSTRATED v Slovenščini - Slovenski prevod

• učinkovitost je bila dokazana
• učinkovitost so dokazali
• učinkovitost so pokazali

Primeri uporabe Efficacy has been demonstrated v Angleški in njihovi prevodi v Slovenski

Its efficacy has been demonstrated in numerous studies.
Njegova učinkovitost je bila dokazana v številnih študijah.

In patients with a single clinical event suggestive of multiple sclerosis, efficacy has been demonstrated over a period of three years.
Pri bolnikih z enim samim kliničnim dogodkom, ki nakazuje multiplo sklerozo, je bila učinkovitost dokazana za obdobje treh let.

Efficacy has been demonstrated with or without concomitant use of methotrexate.
Učinkovitost so dokazali z ali brez sočasne uporabe metotreksata.

Stable complexes can be generated using different types of bi-, tri-, and tetradentate ligand systems, and their efficacy has been demonstrated in vitro and in vivo.[47].
Stabilne komplekse je mogoče ustvariti z uporabo različnih vrst bi-, tri- in tetradentatnih ligandskih sistemov, njihova učinkovitost pa so dokazali in vitro in in vivo.[2].

For relapsing-remitting MS, efficacy has been demonstrated for therapy for the first two years.
Pri recidivno- remitentni multipli sklerozi je dokazana učinkovitost zdravljenja za prvi dve leti.

Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.
Učinkovitost so dokazali pri zdravljenju, ki se je pričelo v dveh dneh po prvem nastopu simptomov.

Clinically proven efficacy on sun vulnerable skin: ANTHELIOS XL efficacy has been demonstrated by 28 clinical studies carried out in vivo by world renowed dermatological experts in photo-dermatology.
Klinično dokazana učinkovitost na koži, ki je občutljiva na sonce. Učinkovitost linije izdelkov Anthelios je bila dokazana v 28 kliničnih študijah, ki so jih izvedli svetovno priznani strokovnjaki s področja foto-dermatologije.

Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to oritavancin in vitro.
Učinkovitost je bila dokazana v kliničnih študijah za naslednje patogene, ki so bili in vitro dovzetni za oritavancin.

In paediatric patients(aged 6 years and above), efficacy has been demonstrated with zonisamide in a double-blind, placebo-controlled study, which included 207 subjects and had a treatment duration of up to 24 weeks.
Pri pediatričnih bolnikih(starih 6 let ali več) so učinkovitost dokazali v dvojno slepi, s placebom kontrolirani študiji z zonisamidom, v katero je bilo vključenih 207 bolnikov, ki se je zdravilo do 24 tednov.

Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to ceftazidime/avibactam in vitro.
Učinkovitost je bila v kliničnih študijah dokazana proti naslednjim patogenom, ki so bili in vitro občutljivi za ceftazidim/avibaktam.

Its anti-ageing efficacy has been demonstrated thanks to a testing protocol inspired by medical research and protected by 7 patents.
Njena učinkovitost proti staranju je bila dokazana z medicinsko podprtim protokolom testov* in okronana s 7 patenti. *Test in vitro.

Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to Zerbaxa in vitro:.
V kliničnih študijah je bila dokazana učinkovitost proti patogenom, ki so našteti pri posamezni indikaciji in so bili in vitro občutljivi na zdravilo Zerbaxa:.

In community acquired pneumonia, efficacy has been demonstrated in a limited number of patients with risk factors such as pneumococcal bacteraemia or age higher than 65 years.
Pri pljučnicah, dobljenih v domačem okolju, je bila učinkovitost dokazana pri omejenem številu bolnikov z dejavniki tveganja, kakršna sta pnevmokokna bakteriemija ali starost nad 65 let.

The efficacy has been demonstrated in idiopathic PAH(IPAH) and in PAH associated connected with connective tissue disease.
Učinkovitost so pokazali pri idiopatskem PAH(IPAH) in pri PAH, povezani s kolagensko vaskularno boleznijo.

The efficacy has been demonstrated in idiopathic PAH(IPAH) and in PAH associated connected with connective tissue disease.
Učinkovitost je bila dokazana pri idiopatski pljučni arterijski hipertenziji(IPAH) in PAH, povezani s sistemsko boleznijo veziva.

Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications$Species with natural intermediate susceptibility.
Klinično učinkovitost so pokazali za občutljive izolate pri potrjenih kliničnih indikacijah $Vrste z naravno srednjo občutljivostjo.

Clinical efficacy has been demonstrated for susceptible isolates of Enterobacter cloacae and Enterobacter aerogenes in approved clinical indications.
Pokazali so klinično učinkovitost za občutljive izolate Enterobacter cloacae in Enterobacter aerogenes pri potrjenih kliničnih indikacijah.

Clinical efficacy has been demonstrated for the following Aspergillus species: Aspergillus fumigatus, flavus, A. niger, and A. terreus(see further below).
Klinična učinkovitost je bila dokazana za naslednje vrste gliv Aspergillus: Aspergillus fumigatus, A. flavus, A. niger,and A. terreus(glejte v nadaljevanju spodaj).

Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to ceftaroline in vitro.
Učinkovitost je bila v kliničnih študijah dokazana proti patogenom, ki so našteti pri posamezni indikaciji in so bili in vitro občutljivi za ceftarolin.

In adults, efficacy has been demonstrated with Zonegran in 4 double-blind, placebo-controlled studies of periods of up to 24 weeks with either once or twice daily dosing.
Pri odraslih je bila učinkovitost zdravila Zonegran prikazana v štirih dvojno slepih, s placebom kontroliranih študijah, ki so trajale do 24 tednov z odmerjanjem enkrat ali dvakrat na dan.

Sonata' s efficacy has been demonstrated in both sleep laboratory studies using objective polysomnography(PSG) measures of sleep and in outpatient studies using patient questionnaires to assess sleep.
Učinkovitost zdravila Sonata je bila dokazana tako v študijah v spalnih laboratorijih z uporabo meritev spanja pri objektivni polisomnografiji(PSG) in v ambulantnih študijah z vprašalniki, v katerih so bolniki ocenjevali svoje spanje.

Superior efficacy has been demonstrated with the combination of pegylated interferon with ribavirin(sustained response rate of 61% achieved in a study performed in naïve patients with a ribavirin dosegt; 10.6 mg/kg, p< 0.01).
Boljša učinkovitost pa se je pokazala pri uporabi pegiliranega interferona v kombinaciji z ribavirinom(trajen virološki odziv 61%, dosežen v študiji, opravljeni pri bolnikih, ki se prej še niso zdravili, z odmerkom ribavirina gt; 10,6 mg/kg, p < 0,01).

Clinical efficacy has been demonstrated for susceptible isolates in the approved clinical indications.$natural intermediate susceptibility+Among MRSA the rate of MLSBc resistant strains is more than 80%, telithromycin is not active against MLSBc.
Klinična učinkovitost je bila dokazana za občutljive izolate pri odobrenih kliničnih indikacijah. $naravna intermediarna občutljivost+ Med MRSA je delež MLSBc odpornih sevov več kot 80%, telitromicin ni aktiven proti MLSBc.

Overall, Cymbalta's efficacy has been demonstrated at daily doses between 60 and 120 mg in a total of five out of seven randomised, double-blind, placebo-controlled, fixed dose acute studies in adult outpatients with major depressive disorder.
Splošno so učinkovitost zdravila Cymbalta pokazali pri dnevnih odmerkih med 60 in 120 mg v skupaj petih od sedmih randomiziranih dvojno slepih s placebom kontroliranih akutnih preskušanjih z določenim odmerkom pri odraslih bolnikih z veliko depresivno motnjo, zdravljenih ambulantno.

Superior efficacy has been demonstrated with the combination of pegylated interferon with ribavirin(sustained response rate of 61% achieved in a study performed in naïve patients with a ribavirin dosegt; 10.6 mg/kg, p< 0.01).
Boljša učinkovitost pa se je pokazala pri uporabi pegiliranega interferona z ribavirinom(v študiji, opravljeni pri bolnikih, ki še niso prejemali tega zdravila, je bil z uporabo ribavirina v odmerku gt; 10, 6 mg/ kg, p < 0, 01 61% dosežen trajen virološki odziv na zdravljenje).

Safety and efficacy have been demonstrated in a long term trial in children aged 1 to less than 18 years.
Varnost in učinkovitost sta bili dokazani v dolgoročnem preskušanju pri otrocih, starih od 1 leta do 18 let.

Safety and efficacy have been demonstrated in a trial in children aged 2 to less than 18 years.
Varnost in učinkovitost sta bili dokazani v dolgoročnem preskušanju pri otrocih, starih od 2 let do 18 let.

(Safety and efficacy have been demonstrated in men between 18 to 41 years of age with mild to moderate hair loss of the vertex and anterior mid scalp area):.
(Varnost in učinkovitost sta bili dokazani pri moških med 18 do 41 letom starosti z blago do zmerno izgubo las na predelu srednjega in prednjega dela lasišča):.

(Safety and efficacy have been demonstrated in men between 18 to 41 years of age with mild to moderate hair loss of the vertex and anterior mid scalp area).
(Varnost in učinkovitost sta dokazali pri moških, starih od 18 do 41 let, z blagimdo zmernim izpadanjem glave vertexa in prednjega dela lasišča).